<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870571</url>
  </required_header>
  <id_info>
    <org_study_id>24309</org_study_id>
    <nct_id>NCT00870571</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess the single-dose relative bioavailability of Actavis Group
      hf and Pfizer (Norvasc®) 10 mg amlodipine besylate tablets, under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.

      Official Title: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study
      of Actavis Group hf and Pfizer Inc. (Norvasc®) 10 mg Amlodipine Besylate Tablets in Healthy
      Adult Volunteers under FedConditions

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NorvasC® 10 mg Tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose</intervention_name>
    <description>A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>amlodipine besylate</other_name>
    <other_name>amlodipine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NorvasC® 10 mg Tablets</intervention_name>
    <description>B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>amlodipine besylate</other_name>
    <other_name>amlodipine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject candidates must fulfill all of the following inclusion criteria to be eligible for
        participation in the study, unless otherwise specified:

          -  Healthy adult male or female volunteers, 18-55 years of age;

          -  Subject will be non-smokers or moderate smokers (less than 10 cigarettes a day) for at
             least 3 months.

          -  Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,
             1983);

          -  Medically healthy subjects with clinically normal laboratory profiles. vital signs and
             ECGs;

          -  Females of childbearing potential should either be sexually inactive (abstinent) for
             14 days prior to the first dose, throughout the study and for 14 days following the
             last dose or be using one of the following acceptable birth control methods:

               1. surgically sterile (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) 6 months minimum.

               2. IUD in place for at least 3 months.

               3. barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to
                  the first dose, throughout the study, and for 14 days following the last dose.

               4. surgical sterilization of the partner (vasectomy for 6 months minimum).

               5. hormonal contraceptives for at least 3 months prior to the first dose of the
                  study and for 14 days following the last dose.

                  Other birth control methods may be deemed acceptable. Postmenopausal women with
                  amenorrhea for at least 2 years will be eligible.

          -  Give voluntary written informed consent to participate in the study.

        Exclusion Criteria:

          -  Subject candidates must not be enrolled in the study if they meet any of the following
             criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

          -  alcoholism or drug abuse within the past year;

          -  hypersensitivity or idiosyncratic reaction to amlodipine or other calcium channel
             blockers.

          -  Female subjects who are pregnant or lactating.

          -  SUbjects who tested positive at screening for HIV, HbsAg or HeV.

          -  Subjects whose sitting blood pressure is less than 110/60 mmHg at screening or 100/55
             mmHg before dosing.

          -  Subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to
             dosing.

          -  Subjects who have used any drugs or substances known to be strong inhibitors of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior to the first
             dose.

          -  Subjects who have used any drugs or substances known to be strong inducers of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

          -  Subjects who have been on a special diet (for whatever reason) during the 28 days
             prior to the first dose and throughout the study.

          -  Subjects who, through completion of the study, would have donated in excess of: 500 mL
             of blood In 14 days; 1500 mL of blood in 160 days; 2500 mL of blood In 1 year.

          -  Subjects who have participated in another clinical trial within 28 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Morelli,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Saint-Laurent, Montreal</city>
        <state>Quebec</state>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&amp;actionHandle=default&amp;nextPage=jsp%2Fchemidlite%2FResultScreen.jsp&amp;responseHandle=JSP&amp;csFldAlias_Alias2=Name&amp;TXTSUPERLISTID=088150429&amp;CHEMICALNAME=Amlodipine&amp;QF1=Name&amp;QO1=%3D&amp;QV1=</url>
    <description>Amlodipine</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>amlodipine besylate</keyword>
  <keyword>amlodipine</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

